Eli Kalif's Insider Trades & SAST Disclosures
Eli Kalif's most recent trade in Teva- Pharmaceutical Industries Ltd. - ADR was a trade of 79,664 Restricted Share Units done . Disclosure was reported to the exchange on March 5, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Eli Kalif.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 79,664 | 79,664 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 21,390 | 459,063 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 21,390 | 0 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 183,169 | 437,673 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 183,169 | 0 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 33,512 | 231,253 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 33,512 | 33,512 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 23,251 | 254,504 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 23,251 | 69,754 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.21 per share. | 28 Feb 2025 | 55,750 | 147,941 (0%) | 0% | 16.2 | 903,462 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 49,800 | 99,602 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 49,800 | 197,741 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 183,169 | 183,169 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.52 per share. | 05 Mar 2024 | 77,550 | 203,691 (0%) | 0% | 13.5 | 1,048,119 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 52,320 | 259,854 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 52,320 | 0 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 21,387 | 21,390 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 21,387 | 281,241 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2024 | 93,005 | 93,005 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 49,800 | 174,022 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 49,800 | 174,022 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 33,512 | 207,534 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 33,512 | 207,534 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 18,430 | 0 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Kalif Eli | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 18,430 | 124,222 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 6,630 | 105,792 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Kalif Eli | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 6,630 | 0 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Eli Kalif | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2024 | 52,320 | 52,320 | - | - | Restricted Share Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges